ECSP088716A - Medicamentos que contienen fluoroquinolonas - Google Patents

Medicamentos que contienen fluoroquinolonas

Info

Publication number
ECSP088716A
ECSP088716A EC2008008716A ECSP088716A ECSP088716A EC SP088716 A ECSP088716 A EC SP088716A EC 2008008716 A EC2008008716 A EC 2008008716A EC SP088716 A ECSP088716 A EC SP088716A EC SP088716 A ECSP088716 A EC SP088716A
Authority
EC
Ecuador
Prior art keywords
fluoroquinolones
medicines containing
quaternary ammonium
containing fluoroquinolones
fluoroquinolone
Prior art date
Application number
EC2008008716A
Other languages
English (en)
Inventor
Iris Heep
Kristine Fraatz
Hans-Juergen Hamann
Markus Edingloh
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38171208&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP088716(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of ECSP088716A publication Critical patent/ECSP088716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La invención se refiere al uso de compuestos de amonio cuaternario para impedir precipitaciones de fluoroquinolonas a partir de sus soluciones, así como a medicamentos estables compatibles, particularmente adecuados para aplicación parenteral, que contienen una fluoroquinolona y un compuesto de amonio cuaternario en forma disuelta.
EC2008008716A 2006-03-08 2008-09-04 Medicamentos que contienen fluoroquinolonas ECSP088716A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006010643A DE102006010643A1 (de) 2006-03-08 2006-03-08 Arzneimittel enthaltend Fluorchinolone

Publications (1)

Publication Number Publication Date
ECSP088716A true ECSP088716A (es) 2008-11-27

Family

ID=38171208

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008716A ECSP088716A (es) 2006-03-08 2008-09-04 Medicamentos que contienen fluoroquinolonas

Country Status (31)

Country Link
US (1) US10231925B2 (es)
EP (2) EP1993510A1 (es)
JP (1) JP5584418B2 (es)
KR (2) KR20080106253A (es)
CN (2) CN104208064A (es)
AR (1) AR059696A1 (es)
AU (1) AU2007291622B2 (es)
BR (1) BRPI0708613B1 (es)
CA (1) CA2645037C (es)
CR (1) CR10270A (es)
DE (1) DE102006010643A1 (es)
DK (1) DK2340809T3 (es)
EC (1) ECSP088716A (es)
ES (1) ES2542206T3 (es)
GT (1) GT200800173A (es)
HU (1) HUE025044T2 (es)
IL (1) IL193429A0 (es)
MX (1) MX2008011344A (es)
MY (1) MY152885A (es)
NZ (1) NZ571046A (es)
PE (1) PE20071021A1 (es)
PL (1) PL2340809T3 (es)
PT (1) PT2340809E (es)
RU (1) RU2527327C2 (es)
SI (1) SI2340809T1 (es)
SV (1) SV2008003014A (es)
TW (1) TWI494105B (es)
UA (1) UA96753C2 (es)
UY (1) UY30191A1 (es)
WO (1) WO2008025380A1 (es)
ZA (1) ZA200807484B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5027983B2 (ja) 2001-05-15 2012-09-19 ユーロケラ エスエヌシー サーモクロミック材料
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
WO2010069493A1 (de) * 2008-12-18 2010-06-24 Bayer Animal Health Gmbh Verbesserte wirkstoffkombination enthaltend ein antibiotikum und einen nichtsteroidalen entzündungshemmer (nsaid)
EP2332916A3 (en) 2009-11-19 2011-08-03 Krka Tovarna Zdravil, D.D., Novo Mesto A process for a preparation of marbofloxacin and intermediate thereof
CN101716141B (zh) * 2010-01-20 2011-11-30 白求恩医科大学制药厂 一种氟罗沙星注射液及其制备方法
GB2480276A (en) * 2010-05-11 2011-11-16 Michael Hilary Burke Process for the preparation of an aqueous injectable enrofloxacin antimicrobial formulation
RU2682171C2 (ru) * 2016-10-11 2019-03-15 Закрытое Акционерное Общество "Биологические Исследования И Системы" (Зао "Бис") Фармацевтическая комбинированная композиция для лечения гнойных ран на основе фторхинолонов (варианты)
CN110113942A (zh) * 2016-11-07 2019-08-09 朱比兰特生命科学有限公司 协同抗微生物组合物
MX387370B (es) * 2017-02-13 2025-03-18 Elanco Animal Health Gmbh Composición líquida que contiene pradofloxacina.
EP3662011A1 (en) 2017-07-31 2020-06-10 Dow Silicones Corporation Moisture curable compositions
WO2019023842A1 (en) 2017-07-31 2019-02-07 Dow Silicones Corporation MOISTURE CURING COMPOSITIONS
CN111620901B (zh) * 2020-06-08 2023-03-21 蚌埠医学院第二附属医院 一种含硅氧烷基的氟喹诺酮化合物、其制备方法及用途
CN119504580A (zh) * 2024-11-25 2025-02-25 华南农业大学 一种二氟沙星及其盐基化合物的晶体及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5746986A (en) 1980-09-02 1982-03-17 Dai Ichi Seiyaku Co Ltd Pyrido(1,2,3-de)(1,4)benzoxazine derivative
US4670444B1 (en) 1980-09-03 1999-02-09 Bayer Ag and-naphthyridine-3-carboxylic acids and antibacte7-amino-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-rial agents containing these compounds
US4472405A (en) 1982-11-12 1984-09-18 Riker Laboratories, Inc. Antimicrobial 6,7-dihydro-5,8-dimethyl-9 fluoro-1-oxo-1H, 5H-benzo (ij) quinolizine-2-carboxylic acid and derivatives
US4730000A (en) 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
US4551456A (en) * 1983-11-14 1985-11-05 Merck & Co., Inc. Ophthalmic use of norfloxacin and related antibiotics
AT392789B (de) 1985-01-23 1991-06-10 Toyama Chemical Co Ltd Verfahren zur herstellung von 1-substituierten aryl-1,4-dihydro-4-oxonaphthyridinderivaten
IN166416B (es) 1985-09-18 1990-05-05 Pfizer
DE3713672A1 (de) * 1987-04-24 1988-11-17 Bayer Ag Verfahren zur herstellung von parenteral verabreichbaren chinoloncarbonsaeuren
DE3831514A1 (de) 1988-09-16 1990-03-22 Bayer Ag Ph-neutrale waessrige loesungen von chinoloncarbonsaeuren
US5225413A (en) * 1988-09-16 1993-07-06 Bayer-Aktiengesellschaft pH-neutral aqueous solutions of quinolone-carboxylic acids
JP2832535B2 (ja) 1989-04-04 1998-12-09 富山化学工業株式会社 キノロンカルボン酸またはその塩の可溶化法
WO1991009616A1 (en) 1989-12-22 1991-07-11 Yale University Quinolone antibiotics encapsulated in lipid vesicles
CA2072366C (en) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Carboxylic acid-metal ion-acid complexes
FR2665635A1 (fr) 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
AU2672892A (en) * 1991-09-17 1993-04-27 Alcon Laboratories, Inc. Compositions containing quinolone antibiotics and sulfonate of polystyrol
DE69618987T2 (de) 1995-12-21 2002-11-21 Pfizer Inc., New York Injizierbare quinolonformulierungen
ATE228130T1 (de) * 1996-02-23 2002-12-15 Bayer Ag Gegebenenfalls substituierte 8-cyan-1-cyclopropyl-7-(2,8-diazabicyclo- 4.3.0)-nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3- hinolincarbonsäuren und ihre derivate
EP0974364A4 (en) 1996-10-25 2000-12-20 Yoshitomi Pharmaceutical METHOD FOR PREVENTING THE PREPARATION OF MEDICINAL PRODUCTS
GB9714218D0 (en) * 1997-07-04 1997-09-10 Allied Therapeutics Ltd Peritoneal dialysis fluid
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
US6387928B1 (en) * 1997-09-15 2002-05-14 The Procter & Gamble Co. Antimicrobial quinolones, their compositions and uses
ATE423776T1 (de) * 1997-09-15 2009-03-15 Procter & Gamble Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
US6605751B1 (en) * 1997-11-14 2003-08-12 Acrymed Silver-containing compositions, devices and methods for making
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
DE19918324A1 (de) * 1999-04-22 2000-10-26 Mann Gerhard Chem Pharm Fab Pharmazeutische Zusammensetzung wirksam gegen durch Bakterien, Viren, Pilze, Hefen und Protozoen verursachte Krankheitszustände
US6482799B1 (en) * 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
EP1214056B1 (en) * 1999-09-24 2003-10-29 Alcon Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
DE10312346A1 (de) * 2003-03-20 2004-09-30 Bayer Healthcare Ag Kontrolliertes Freisetzungssystem
RU2248199C1 (ru) * 2003-06-02 2005-03-20 Открытое Акционерное Общество "Акционерное Курганское общество медицинских препаратов и изделий "Синтез" (ОАО "Синтез") Глазные капли и способ их получения
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
DE102004015981A1 (de) 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
CN101039668A (zh) * 2004-08-13 2007-09-19 先灵-普劳有限公司 包含抗菌素、三唑和皮质类固醇的药物制剂

Also Published As

Publication number Publication date
HUE025044T2 (en) 2016-01-28
KR20080106253A (ko) 2008-12-04
CN101394836A (zh) 2009-03-25
CA2645037A1 (en) 2008-03-06
ZA200807484B (en) 2009-11-25
RU2527327C2 (ru) 2014-08-27
TW200810756A (en) 2008-03-01
CR10270A (es) 2009-03-18
US20100009979A1 (en) 2010-01-14
PT2340809E (pt) 2015-08-28
US10231925B2 (en) 2019-03-19
EP2340809B1 (de) 2015-04-15
AU2007291622B2 (en) 2013-08-01
EP2340809A3 (de) 2012-09-19
PL2340809T3 (pl) 2015-09-30
SV2008003014A (es) 2010-05-17
TWI494105B (zh) 2015-08-01
SI2340809T1 (sl) 2015-08-31
CN101394836B (zh) 2017-08-29
DE102006010643A1 (de) 2007-09-13
PE20071021A1 (es) 2007-11-25
WO2008025380A1 (de) 2008-03-06
MX2008011344A (es) 2008-11-12
JP2009529015A (ja) 2009-08-13
AU2007291622A1 (en) 2008-03-06
AR059696A1 (es) 2008-04-23
BRPI0708613A2 (pt) 2011-06-07
CN104208064A (zh) 2014-12-17
EP1993510A1 (de) 2008-11-26
GT200800173A (es) 2009-09-14
IL193429A0 (en) 2009-05-04
MY152885A (en) 2014-11-28
BRPI0708613B1 (pt) 2021-10-19
JP5584418B2 (ja) 2014-09-03
UA96753C2 (ru) 2011-12-12
KR20150046367A (ko) 2015-04-29
CA2645037C (en) 2016-06-28
ES2542206T3 (es) 2015-08-03
EP2340809A2 (de) 2011-07-06
DK2340809T3 (en) 2015-07-20
UY30191A1 (es) 2007-10-31
RU2008139635A (ru) 2010-04-20
NZ571046A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
CR10270A (es) Medicamentos que contienen fluoroquinolonas
BRPI0810646A2 (pt) " compostos farmacêuticos ".
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0811712A2 (pt) "composto, processo de preparação de um composto e composição farmacéutica".
DK3045164T3 (da) Vandige farmaceutiske sammensætninger, der indeholder borat-polyol-komplekser
BRPI0921365A2 (pt) cartucho, um dispensador de produtos farmacêuticos que contém o cartucho, bem como as aplicações do catucho e do dispensador de produtos farmacêuticos.
GT200800251A (es) Nitrilos espirociclicos como inhibidores de proteasa
UA98623C2 (ru) Соединения диосметина, способ их получения и фармацевтическая композиция, которая их содержит
DOP2011000329A (es) Preparacion de solido
UY32187A (es) Composiciones farmaceuticas topicas
ECSP088722A (es) Formulaciones medicamentosas que contienen fluoroquinolonas
UY30424A1 (es) Derivados de quinolina, su preparacion, su uso y medicamentos que comprenden los mismos.
BR112012013319A2 (pt) derivados espiro azacíclicos
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
BRPI0821116B8 (pt) composto, composição farmacêutica que o contem, uso deste e processo para a preparação do mesmo
BRPI0821197A2 (pt) Composto, composição farmacêutica, uso de um composto, processo, e, intermediário.
BRPI0918399A2 (pt) composto antagonista do receptor de esfingosina-1-fosfato (s1p), bem como composição farmacêutica e uso do mesmo
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
BRPI0916702A2 (pt) composto, uso de um composto, e, composição farmacêutica.
BRPI0810871A2 (pt) Composto, processo de preparação de um composto, composição farmacêutica e utilização de um composto.
NO20064783L (no) Opplosningstabeletter med licarbazepin
EA201301021A1 (ru) Применение пригодной для распыления композиции, содержащей амброксол